Navigation Links
AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
Date:6/8/2009

o pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements, and we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested to do so by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Research ... the addition of Jain PharmaBiotech,s new report ... to their offering. The ... fluorescence in situ hybridization (FISH), comparative genomic ... includes application of nanobiotechnology, microarrays, real-time polymerase ...
(Date:9/2/2015)... 2015 Aytu BioScience, Inc. (OTCQB: AYTU), a ... and related conditions, announced today that it has closed ... note financing, raising a total of $5.175 million, which ... Josh Disbrow , Chief Executive ... are intended to be used to conduct clinical studies ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in medical ... From vital sign monitoring in ICU to 3D skull printing analysis for Neurosurgery, ... real-time clinical decisions with simultaneous access to high precision medical images and electronic ...
(Date:9/1/2015)... Swecure, ein Biotechnologieunternehmen, ... Entwicklung neuartiger Therapien für Störungen des Immunsystems ... konzentriert, erhält vom US Patent and Trademark ... patentiert wird. Das Medikament basiert auf einem ... und Entzündungen vorbeugt.   Das Medikament, ...
Breaking Biology Technology:Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... 26, 2009): An experimental drug, LX211 (LUVENIQ; oral voclosporin), ... modifying the course of uveitis, a group of serious ... or substantial morbidity from steroid use. Results of international ... be the subject of two podium presentations at the ...
... CRANBURY, N.J., Oct. 29 Amicus Therapeutics (Nasdaq: ... quarter 2009. Additionally, Amicus also today announced that ... from its partner, Shire, for its lead lysosomal storage ... termination of their collaboration. The Company also announced ...
... BioSciences Inc. (NYSE Amex: YMI ; TSX: YM), ... advances a diverse portfolio of promising cancer-related products at ... a completed phase III study of nimotuzumab in children ... the preliminary data at ASCO 2008 were presented by ...
Cached Biology Technology:LX211 highlighted as potential disease modifying therapy for noninfectious uveitis 2LX211 highlighted as potential disease modifying therapy for noninfectious uveitis 3Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 2Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 3Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 4Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 5Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 6Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 7Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 8Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 9Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 10Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 11Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 12Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 13YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 2YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 3YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 4
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the ... Second quarter contract revenue of $ 85.2 ... contract margins of 26 % , Second ... EPS from royalties in the current quarter , ... very pleased to present another strong financial quarter, with all our ...
(Date:7/31/2015)... , 31 de julho de 2015 ... www.icg-10.org ) será realizada pela BGI de 22-25 de ... . A conferência está celebrando seu 10 ... 2006, a ICG se tornou uma das reuniões mais ... dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... of Arizona and Columbia University have discovered that tiny ... forces far stronger than experts had previously thought possible. ... a member of the BIO5 Institute and the department ... Type IV pili or filaments on the ...
... pathways that allow an errant gene to turn a cell ... single enzyme called the p21-activated kinase 1, or PAK1. ... a molecule capable of shutting down PAK1 before the enzyme ... breast cancer and have shown the enzyme is important in ...
... spacecraft SOHO shows clearly that powerful starquakes ripple around the ... above its surface. The observations give solar physicists new insight ... way of studying other stars. The outermost quarter of ... gas. Turbulence in this region causes ripples that criss-cross the ...
Cached Biology News:University of Arizona scientist shares in discovery of microbe filaments' power 2Fox Chase researchers discover a method for clamping down on a cancer-promoting enzyme 2Fox Chase researchers discover a method for clamping down on a cancer-promoting enzyme 3Solar flares set the Sun quaking 2
...
...
Rabbit polyclonal to Staphylococcus Enterotoxin E (Biotin) ( Abpromise for all tested applications)....
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
Biology Products: